Updated on 20 April 2016
(Photo Courtesy: www.videohive.net)
The company's latest report states that the approval and uptake of immuno-oncology products is set to burgeon due to increased recognition of their long and durable tumor responses, which are similar to targeted therapies.
Furthermore, these treatments have shown efficacy in a wide variety of indications and are not associated with the adverse side effects produced by traditional chemotherapy such as fatigue, neutropenia, or alopecia.
Dr Dan Roberts, GlobalData's Senior Analyst covering Oncology and Hematology, says: "Immuno-oncology products have demonstrated comparable respective efficacy and safety profiles, so their commercial success will largely rest on the speed with which they enter the market, their clinical and commercial positioning, target patient populations, and the marketing power of the relevant pharmaceutical company."
Ono/Bristol-Myers Squibb's Opdivo and Schering Plough/Merck and Co.'s Keytruda are set to be the highest-selling immuno-oncology drugs, with GlobalData forecasting multi-blockbuster sales of around $10 billion and $7 billion by 2024, respectively.
Dr Roberts explains: "Both therapies, which are programmed cell death protein-1 (PD-1) inhibitors, will achieve such impressive sales due to the fact that they will be first-to-market in many indications, transcending competition such as Roche's atezolizumab and AstraZeneca's durvalumab.